(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 March 2012 (29.03.2012)

PCT

(10) International Publication Number
WO 2012/038606 A1

(51) **International Patent Classification**:
C12N 15/861 (2006.01) *C07K 16/28* (2006.01)

(21) **International Application Number**:
PCT/FI2011/050822

(22) **International Filing Date**:
23 September 2011 (23.09.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
20105991 24 September 2010 (24.09.2010) FI
20115454 11 May 2011 (11.05.2011) FI

(71) **Applicant** *(for all designated States except US)*: **ONCOS THERAPEUTICS OY** [FI/FI]; Saukonpaadenranta 2, FI-00180 Helsinki (FI).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **DIAS, Joao** [PT/FI]; Tilkankatu 7 A 2, FI-00300 Helsinki (FI). **CERULLO, Vincenzo** [IT/FI]; Uimarinpolku 10 C 15, FI-00330 Helsinki (FI). **HEMMINKI, Akseli** [FI/FI]; Pohjoinen Hesperiankatu 37 A 22, FI-00260 Helsinki (FI). **PESONEN, Sari** [FI/FI]; Svinhufvudintie 2 A 1, FI-00570 Helsinki (FI).

(74) **Agent**: **KOLSTER OY AB**; ISO Roobertinkatu 23, P.O. Box 148, FI-00121 Helsinki (FI).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,

[Continued on next page]

(54) **Title**: ONCOLYTIC ADENOVIRAL VECTORS CODING FOR MONOCLONAL ANTI - CTLA - 4 ANTIBODIES




Figure 1

(57) **Abstract**: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to said vectors for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing monoclonal anti-CTLA4 antibodies in a cell and increasing tumor specific immune response and apoptosis in a subject, as well as uses of the oncolytic adenoviral vectors for producing monoclonal anti-CTLA4 antibodies in a cell and increasing tumor specific immune response and apoptosis in a subject.

WO 2012/038606 A1

ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*